Hansong Dong | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Hansong Dong | Host-Pathogen Interactions | Best Researcher Award

Prof. Hansong Dong, Shandong Agricultural University, China

Dr. Hansong Dong is a distinguished Professor of Plant Pathology and Doctoral Supervisor at Shandong Agricultural University, China. With a Ph.D. in Plant Pathology, his work spans over four decades, focusing on plant immunity, signal transduction, and the balance between crop growth and defense. A renowned researcher and published poet, Prof. Dong has made seminal contributions to our understanding of aquaporins, hormone signaling, and the molecular interface between host plants and pathogens. His international academic exposure, including time as a Visiting Scholar at Cornell University, has further enriched his scientific insights. In addition to his impactful research, Prof. Dong has mentored numerous graduate students and contributed to agricultural innovation. With numerous high-impact publications in journals like Molecular Plant and New Phytologist, his work is widely recognized. Beyond academia, his literary works reflect a philosophical appreciation of nature and resilience, exemplifying a rare integration of science and art.

Publication Profile: 

Scopus

Education:

Prof. Hansong Dong pursued his undergraduate studies in Plant Protection at Shandong Agricultural University (1978–1982). He continued with his Master’s and Ph.D. in Plant Pathology at Nanjing Agricultural University, completing them in 1985 and 1988, respectively. His academic training provided a solid foundation in plant-microbe interactions, molecular biology, and host defense mechanisms. During his studies, he honed his focus on understanding plant immune responses, laying the groundwork for his future breakthroughs in signaling and aquaporin-mediated defense. His Ph.D. thesis contributed to early models of pathogen-host dynamics in crops, marking the start of a lifelong research trajectory in agricultural biotechnology. His formal education not only established his credibility in plant pathology but also shaped his vision for interdisciplinary research. Prof. Dong’s academic excellence has continued to drive forward key discoveries in the field, making him a leading authority in crop protection and molecular plant immunity in China and internationally.

Experience:

Prof. Dong began his career as a Lecturer in the Department of Plant Pathology at Shandong Agricultural University (1988–1993). He quickly rose through academic ranks—Associate Professor in 1993, and full Professor by 1994. His leadership and research capabilities were recognized early on, leading to a Visiting Scholar position at Cornell University (1997–2000), where he engaged in collaborative projects on plant immune signaling and pathogen effectors. Over his decades of teaching and research, Prof. Dong has supervised numerous doctoral students, published extensively, and shaped academic policy and curriculum in plant pathology. His tenure at Shandong Agricultural University is marked by scientific rigor, mentorship, and impactful agricultural innovations. His ability to bridge laboratory research with field application has contributed significantly to crop disease management strategies in China. Prof. Dong remains actively involved in national and international research initiatives, playing a vital role in advancing molecular plant pathology and crop resilience.

Awards & Honors:

Prof. Hansong Dong has received several prestigious accolades recognizing his early and sustained contributions to science and education. In 1992, he was honored as an Outstanding Young Intellectual and received the Shandong Youth Science and Technology Award, acknowledging his early promise in agricultural research. The same year, he was also named an Excellent Young Teacher, a testament to his pedagogical contributions. In 1993, he was recognized as a New Long March Commando, symbolizing excellence in youth-led scientific advancement in China. These early recognitions paved the way for a prolific academic career that has garnered respect across disciplines. His awards highlight his leadership in scientific innovation, commitment to nurturing the next generation of researchers, and the societal relevance of his work in safeguarding global food security. As both a scientist and educator, Prof. Dong’s accolades reflect his well-rounded excellence and continued influence in plant pathology and agronomic science.

Research Focus:

Prof. Dong’s research focuses on signal transduction in plant disease resistance and the regulation of growth-defense trade-offs in crops. His work investigates the molecular dialogue between plants and pathogens, particularly through the lens of aquaporins, importins, and membrane proteins. He has significantly advanced our understanding of how pathogenic effectors manipulate host splicing and hormone pathways, notably through TAL effectors and NPR1/NPR3 systems in rice. His team applies multi-omics and CRISPR-based editing to engineer resistant crops while minimizing yield penalties, a critical goal in sustainable agriculture. By elucidating the roles of H2O2 transport, type-III secretion systems, and transcriptional regulation, his research offers translational solutions to fungal and bacterial diseases in cereals like rice and wheat. Prof. Dong’s innovative blend of molecular biology, bioinformatics, and field experimentation drives progress toward disease-resilient, high-yield crops. His collaborative, systems-level approach continues to shape modern plant pathology and crop biotechnology.

 Publications Top Notes:

  1. Alternative splicing of OsNPR3… enhances disease susceptibility in rice – Molecular Plant, 2025

  2. Plant PI4P is required for bacteria to translocate type-3 effectors – New Phytologist, 2025

  3. MYB44 regulates PTI via EIN2 and MPK3/6 in Arabidopsis – Plant Communications, 2023

  4. Importin β1 mediates nuclear entry of EIN2C against aphids – IJMS, 2023

  5. Phosphorylation of wheat aquaporin enhances growth and defense – Molecular Plant, 2022

  6. Aquaporin OsPIP2;2 links H2O2 signaling to plant defense – Plant Physiology, 2022

  7. Editing rice importin IMPα1b sequesters TAL effectors – Phytopathology Research, 2022

  8. Aquaporin modulation intensifies photosynthesis and disease resistance – Plant Journal, 2021

  9. OsPIP2;2 facilitates drought tolerance in rice – Plant Direct, 2021

  10.  Aquaporin TaPIP2;10 confers dual fungal resistance in wheat – Phytopathology, 2021

Conclusion:

Prof. Hansong Dong is highly suitable for the “Best Researcher Award.” His scholarly depth, sustained academic leadership, groundbreaking findings in plant pathology, and dedication to mentoring make him a standout candidate. His career exemplifies a blend of scientific rigor, poetic vision, and global relevance. Recognizing Prof. Dong would not only honor an exceptional researcher but also inspire younger generations in the intersection of science and humanity.

Takwa Wannassi | Plant pathology | Best Researcher Award

Published on by Cell Biologist

Dr. Takwa Wannassi | Plant pathology | Best Researcher Award

Dr. Takwa Wannassi, CRRA Sidi Bouzid, Tunisia

Dr. Takwa Wannassi is a dedicated plant protection specialist and postdoctoral researcher at the Regional Center of Agricultural Research in Sidi Bouzid, Tunisia. With a Ph.D. in Plant Protection and Environment and an Engineering Degree in Horticulture, she brings advanced expertise in entomology, plant-microbe interactions, and sustainable agriculture. Her work is primarily focused on integrated pest management and ecological approaches to crop protection, particularly in Mediterranean agroecosystems. Dr. Wannassi has authored several impactful scientific publications and has contributed significantly to the understanding of invasive pest dynamics, particularly the apricot seed wasp. She plays a crucial role in the international PRIMA project “REVINE,” where she coordinates field trials, mentors students, and collaborates across scientific disciplines. Her dedication to sustainable farming solutions, her extensive research record, and her collaborative spirit make her a strong candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar
Scopus
Orcid

Education:

Dr. Takwa Wannassi holds a Ph.D. in Plant Protection and Environment from Sousse University, Higher Institute of Agronomic Sciences of Chott Mariem (ISA-CM), completed in December 2022. Her doctoral work centered on invasive species and sustainable pest management in Tunisia, particularly the apricot seed wasp Eurytoma samsonowi. She also holds an Engineer Degree in Horticulture with a specialization in Plant Protection, earned in July 2017 from the same institution. Her academic journey reflects a consistent focus on understanding ecological challenges in agriculture and developing innovative, sustainable solutions. Through both degrees, she acquired hands-on skills in molecular biology, field experimentation, pest identification, and biological control. Her academic excellence laid the foundation for her impactful contributions in agricultural research and sustainability science in the Mediterranean region.

Experience:

Since January 2025, Dr. Takwa Wannassi has been serving as a postdoctoral fellow at the Regional Center of Agricultural Research in Sidi Bouzid (CRRA), Tunisia, contributing to the international PRIMA Project “REVINE.” Her responsibilities include coordinating the research project, supervising graduate students, conducting field and lab trials, and analyzing data using R. Her work spans genomic analysis, molecular diagnostics, pest ecology, and microbiome studies. Previously, during her Ph.D., she gained extensive experience in pest ecology, molecular biology, and entomology, particularly in relation to invasive pests such as Eurytoma samsonowi. Dr. Wannassi also collaborates with international institutions, including during a research fellowship in Canada. She is proficient in preparing scientific publications and has presented her findings at major international conferences. Her multidisciplinary approach and leadership in sustainable agriculture research have earned her recognition at both national and international levels.

Awards and Honors:

Dr. Takwa Wannassi has received several accolades in recognition of her contributions to agricultural science and research. In 2019, she earned the Best Poster Award at the Tunisia-Japan Symposium on Science, Society and Technology (TJASSST) for her research on pest behavior and pheromone-based management strategies. That same year, she was granted a Research Fellowship in Canada, allowing her to work at the University of Victoria, British Columbia for two months, enhancing her international research exposure and collaboration. Her continuous efforts in sustainable pest management, microbiome studies, and plant-pathogen interaction have positioned her as a promising researcher in plant protection. She is frequently invited to contribute to scientific conferences and peer-reviewed journals. Her achievements underline her scientific innovation, dedication to eco-agriculture, and her potential as a future leader in Mediterranean agricultural research.

Research Focus:

Dr. Takwa Wannassi’s research centers on plant protection, pest ecology, biological control, and plant-microbiome interactions, with a strong focus on sustainability. Her main scientific interest lies in understanding the behavior and biology of invasive pests like Eurytoma samsonowi, a major threat to apricot production in Tunisia. She utilizes molecular tools, including 16S rRNA sequencing, to explore bacterial communities and Wolbachia infections in pest populations. Additionally, she investigates the role of beneficial rhizobacteria and microbial consortia in disease suppression and grapevine health as part of the PRIMA “REVINE” project. Through multidisciplinary approaches, she integrates entomology, microbiology, and bioinformatics to develop innovative pest management strategies aligned with climate-smart agriculture. Her goal is to promote ecosystem services, biodiversity, and resilience in Mediterranean cropping systems through regenerative and eco-friendly practices.

Publications Top Notes: 

  1. Insights on the bioecology of the invasive apricot seed wasp Eurytoma samsonowi in Tunisia (Biologia, 2023)

  2. Emergence of the apricot seed wasp Eurytoma samsonowi as an economic pest of apricots in Tunisia (Phytoparasitica, 2022)

  3. Prevalence of Wolbachia infection in field populations of the apricot seed wasp (International Microbiology, 2024)

  4. Exploration of bacterial composition and diversity within Eurytoma samsonowi via 16S rRNA sequencing (Symbiosis, 2025)

  5. Harnessing a Microbial Consortium and Compost to Control Grapevine Pathogens (Horticulturae, 2025)

  6. Investigating the potential role of beneficial rhizobacteria for grapevine health and growth (Frontiers in Sustainable Food Systems, 2025)

  7. Biocontrol Assessment of Trichoderma Species on Tomato Crops Infested by Curvularia Spicifera (Frontiers, 2025)

  8. Divergent bacterial abundance and diversity in Eurytoma samsonowi revealed by 16S rRNA (Biochem & Microbiology Congress)

  9. Assessment of damage by Eurytoma samsonowi on apricot fruits in Tunisia (INAT Symposium Poster, 2018)

  10.  Delta traps with virgin females attract Eurytoma samsonowi males: Pheromone control potential (TJASSST, 2019)

Conclusion:

Dr. Takwa Wannassi is an emerging leader in plant protection and agroecology, with a proven record of excellence in research, publishing, and project management. Her work on invasive pest control, microbial consortia, and regenerative viticulture directly addresses critical challenges in Mediterranean and global agriculture. Her multidisciplinary approach, international recognition, and active mentorship highlight her readiness for continued leadership in science. She is highly suitable and deserving of the Best Researcher Award, as she exemplifies innovation, academic rigor, and a commitment to sustainable agricultural development.

Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Assoc. Prof. Dr. Cesare Orlandi, University of Rochester, United States

Dr. Cesare Orlandi is an accomplished Associate Professor of Pharmacology and Physiology at the University of Rochester School of Medicine & Dentistry. With a multidisciplinary background in pharmaceutical biotechnology and molecular genetics, Dr. Orlandi has made significant contributions to GPCR (G protein-coupled receptor) biology, orphan receptor deorphanization, and signal transduction. His work bridges basic molecular pharmacology with translational applications in neuroscience and immunology. He has authored numerous high-impact publications in leading journals like Science, Nature Communications, and Journal of Medicinal Chemistry. His collaborative research with global institutions reflects a strong network and broad scientific reach. Recognized for his excellence in science communication, Dr. Orlandi has received multiple “Best Talk” awards at competitive research symposia. His lab continues to innovate at the frontier of receptor biology, influencing therapeutic strategies in neurobiology and inflammation.

Publication Profile: 

Scopus

Orcid

Strengths for the Award:

  1. High-Impact Publications in Prestigious Journals
    Dr. Orlandi has published in top-tier, peer-reviewed journals, including Science, Nature Communications, PNAS, Journal of Physiology, and Molecular Pharmacology. This reflects the scientific rigor, innovation, and broad relevance of his work.

  2. Research Innovation in GPCR Biology
    His research into orphan G protein-coupled receptors (GPCRs) has led to the development of new experimental assays (e.g., GzESTY) and has provided significant insights into immune and neurological signaling mechanisms. These contributions are not only fundamental but also highly translational, aligning with drug discovery and therapeutic interventions.

  3. Strong Interdisciplinary and Collaborative Profile
    Dr. Orlandi’s collaborations with diverse teams across pharmacology, structural biology, and immunology underscore his interdisciplinary approach. His name appears alongside experts from multiple institutions, showing leadership in team science.

  4. Recognition for Scientific Communication
    His awards for Best Talk at Scripps Research Fest (2016, 2018) and selection for a Gordon Research Seminar oral presentation affirm his strength in communicating complex science effectively—an essential trait for broader impact.

  5. Mentorship and Leadership
    As an Associate Professor at the University of Rochester, Dr. Orlandi plays an active role in training the next generation of biomedical researchers, contributing to capacity building in academia.

Areas for Improvement:

  1. Limited Mention of Funding Sources or Grant Leadership
    While his publication record is excellent, there’s no clear listing of major research grants or principal investigator (PI) roles, which are critical markers for research independence and sustainability.

  2. More Visible Clinical or Translational Output
    While his work is biologically impactful, the clinical translation or patenting aspect could be made more visible to demonstrate tangible applications beyond academic impact.

  3. Leadership in International Consortia or Editorial Boards
    Additional involvement in editorial boards, scientific committees, or research policy advisory roles would further bolster his profile as a leader in his field.

Education:

Dr. Orlandi earned his Ph.D. in Molecular Genetics from the University of Brescia, Italy (2005–2009), where he conducted foundational research into genetic signaling mechanisms. Prior to that, he completed a Master of Science in Pharmaceutical Biotechnology at the University of Milan (1998–2004), equipping him with a robust interdisciplinary foundation in drug development, pharmacodynamics, and molecular biology. His academic path reflects a strong European biomedical training system, with emphasis on translational pharmacology and therapeutic innovation. The combination of pharmaceutical science and genetic research uniquely positions Dr. Orlandi to explore receptor biology with a precision medicine lens. His training was further strengthened by postdoctoral research in elite institutions, where he deepened his specialization in orphan GPCR signaling. This education forms the backbone of his research productivity and ability to mentor the next generation of molecular pharmacologists.

Experience:

Dr. Cesare Orlandi currently serves as Associate Professor in the Department of Pharmacology and Physiology at the University of Rochester. He has established himself as a leading voice in the GPCR research community, especially in understanding orphan receptors and their roles in neuronal and immune systems. Prior to this, he held postdoctoral and research positions where he collaborated with global leaders in receptor signaling and neurobiology. His lab combines pharmacological, molecular, and computational approaches to tackle fundamental questions about receptor activity, bias, and downstream signaling. With over a decade of hands-on research experience and extensive publication output, Dr. Orlandi has trained graduate students and postdocs who have progressed into independent academic and industry positions. His multidisciplinary experience spans receptor pharmacology, molecular neuroscience, and drug discovery, making him a cornerstone in collaborative biomedical research projects at the University of Rochester and beyond.

Awards and Honors:

Dr. Orlandi’s scientific excellence has been recognized with several prestigious honors. Notably, he received the Best Talk Award at the Scripps Research Fest in both 2016 and 2018, underscoring his ability to clearly and impactfully communicate complex scientific findings. In 2016, his work was also selected for an oral presentation at the highly competitive Gordon Research Seminar on Phosphorylation and G-Protein Mediated Signaling, affirming the novelty and relevance of his contributions to the receptor signaling field. These awards highlight not only the depth of his scientific insights but also his excellence in mentorship, collaboration, and thought leadership. They place him among a select group of researchers with both technical and communicative brilliance, a critical trait for academic and translational science leadership. These recognitions, combined with high-impact publications, position Dr. Orlandi as a deserving candidate for the Best Researcher Award.

Research Focus:

Dr. Orlandi’s research revolves around orphan G protein-coupled receptors (GPCRs)—a class of proteins that are vital drug targets but remain largely unexplored. His lab develops novel assays (like GzESTY) for GPCR deorphanization, helping decode their physiological roles in the brain and immune system. He also explores signaling bias, investigating how different ligands induce distinct signaling cascades through the same receptor. His recent work uncovered pivotal roles for orphan GPCRs in macrophage immune function and neuronal communication, highlighting their therapeutic potential. Collaborating across pharmacology, neuroscience, and structural biology, he integrates in vitro, in vivo, and computational methods. His lab has also contributed to understanding how GPCRs interact with psychoactive cannabinoids and prostaglandins, which has implications for pain, inflammation, and psychiatric disorders. His research is highly translational, aiming to inform next-generation drug discovery in neuropharmacology and immunomodulation.

Publications Top Notes: 

  1. 🧬 Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons – Journal of Medicinal Chemistry, 2025

  2. 🧪 Pancreatic Exocrine Signaling and Function Require Gαq Activation – The Journal of Physiology, 2025

  3. 🧫 GzESTY: An Optimized Cell-Based Assay for GPCR Deorphanization – Nature Communications, 2025

  4. 🧉 Orphan GPCR GPRC5B Controls Macrophage Function via Prostaglandin E2 Signaling – Nature Communications, 2025

  5. 🧠 Gα Protein Signaling Bias at the 5-HT1A Receptor – Molecular Pharmacology, 2023

  6. 🧠 Spatial Profile of Orphan GPCR GPRC5B Expression in Mouse Brain – Frontiers in Neuroscience, 2022

  7. 🔍 In Vitro Profiling of Orphan GPCR Constitutive Activity – British Journal of Pharmacology, 2021

  8. 🧩 Cell-Adhesion Molecules Regulate Cone Photoreceptor Synaptic Wiring – PNAS, 2020

  9. 🎮 NF1-cAMP Signaling Links Striatal Neurons to Reward and Motor Control – PLOS Biology, 2019

  10. 🚫 Genetic Behavioral Screen Identifies an Orphan Anti-Opioid System – Science, 2019

Conclusion:

Dr. Cesare Orlandi stands out as an exceptional researcher whose work has advanced the frontiers of molecular pharmacology, especially in the complex field of orphan GPCRs. His innovative methodologies, strong publication track record, and interdisciplinary collaborations make a compelling case for recognition through the Best Researcher Award. While there is room to further highlight his grant leadership and translational reach, his scientific output and leadership are already at a level that merits this award.

Weili Miao | RNA biology | Best Researcher Award

Published on by Cell Biologist

Dr. Weili Miao | RNA biology | Best Researcher Award

Dr. Weili Miao, Stanford University, United States

Dr. Weili Miao is an accomplished molecular biologist with a focus on RNA biology, biomolecule interactions, and translational control. She earned her Ph.D. in Chemistry from the University of California, Riverside, and currently serves as a postdoctoral researcher at Stanford University. Her work has uncovered novel functions of biomolecule interactions in gene expression, with implications for tissue differentiation and disease. Dr. Miao’s high-impact publications in Cell, Nature Communications, and Nucleic Acids Research reflect her technical rigor and creativity. She is a recipient of the prestigious NIH K01 Award and has developed state-of-the-art techniques like irCLIP-RNP and PROBER. Her interdisciplinary research bridges chemistry, biology, and medicine, making significant strides in understanding gene regulation mechanisms. Dr. Miao is an emerging leader in her field and continues to inspire with her meticulous research and impactful discoveries.

Publication Profile: 

Google Scholar

scopus

Strengths for the Award:

  1.  Outstanding Publication Record:
    Dr. Miao is first or co-first author on multiple high-impact publications in top-tier journals such as Cell, Nature Communications, Nature Reviews Molecular Cell Biology, and Nucleic Acids Research. These reflect cutting-edge research on RNA-protein interactions and gene regulation.

  2.  Innovative Method Development:
    She has contributed to the development and application of innovative molecular tools including easy-CLIP, irCLIP-RNP, PROBER, and MST—advancing the technical landscape for RNA/DNA-protein interaction studies.

  3.  Novel Biological Discoveries:
    Her discoveries, particularly regarding glucose’s unexpected regulatory role in RNA-binding proteins such as DDX21, DDX50, and NSUN2, have significantly advanced our understanding of metabolic-epigenetic regulation in tissue differentiation.

  4.  Prestigious Funding:
    Recipient of the NIH K01 Mentored Research Scientist Development Award (2024–2029), highlighting her potential for becoming an independent research leader.

  5.  Cross-Disciplinary Collaboration:
    Extensive collaborations across structural biology, biochemistry, and systems biology with prominent labs at Stanford, showcasing her integrative approach and strong team science credentials.

Areas for Improvement:

  1.  Global Science Communication:
    Greater involvement in public science engagement, outreach, or policy translation could expand the societal impact of her work.

  2.  Independent Research Leadership:
    While she has secured the NIH K01 award, leading a research group or mentoring postdoctoral scholars would further elevate her academic stature.

  3.  Translational Impact:
    Strengthening clinical or translational applications of her findings—particularly in cancer or metabolic disease—could increase her visibility in applied biomedical research.

Education:

Dr. Weili Miao completed her Ph.D. in Chemistry at the University of California, Riverside in May 2019, where she specialized in proteomics and biomolecular interactions. During her doctoral studies, she developed quantitative proteomic techniques to study kinase activity and m6A modifications, contributing significantly to our understanding of stress responses and cancer biology. Prior to her Ph.D., she earned her Bachelor of Science in Chemistry from the prestigious Fudan University, China, in June 2014. Her educational background blends a strong foundation in chemistry with advanced molecular biology, enabling her to approach scientific questions with precision and innovation. Her academic training has been instrumental in driving her postdoctoral research in RNA-protein interaction networks and biomolecule regulation. These formative experiences laid the groundwork for her high-impact contributions to biomedical science and continue to support her trajectory as an independent investigator.

Research Experience:

Since September 2019, Dr. Weili Miao has been a Postdoctoral Researcher at Stanford University, where she explores how biomolecules such as glucose regulate RNA- and DNA-binding proteins. Her pioneering discoveries revealed that glucose binds DDX21, DDX50, and NSUN2, influencing mRNA splicing and epidermal differentiation. She has expertly incorporated advanced methodologies like irCLIP-RNP, easy-CLIP, PROBER, and MST, contributing to a deeper understanding of RNA biology and epigenetics. Prior to this, her Ph.D. work at UC Riverside involved proteome-wide characterization of kinase activity and m6A RNA modifications in stress and cancer contexts. Her work stands out for both technical innovation and biological relevance. Dr. Miao’s interdisciplinary background in proteomics, RNA biology, and structural biochemistry positions her at the forefront of biomedical discovery. She collaborates with leaders in the field and contributes to major scientific consortia, demonstrating a trajectory of excellence and leadership in research.

Awards and Honors:

Dr. Weili Miao has received numerous prestigious honors recognizing her scientific excellence and research promise. In 2024, she was awarded the NIH K01 Mentored Research Scientist Development Award (2024–2029), affirming her potential as a future independent investigator. During her Ph.D. at UC Riverside, she earned the Dissertation Year Program Fellowship (2018–2019), recognizing her outstanding doctoral research. In 2019, she received the Award for Outstanding Self-financed Students Abroad, a highly competitive honor granted by the Chinese government to top-performing international scholars. These accolades reflect her consistent high-impact research and innovation in RNA biology, proteomics, and biomolecule interaction networks. Her ability to secure national-level funding and recognition at every stage of her career demonstrates a rare combination of technical expertise, leadership, and strategic research vision. Dr. Miao’s honors not only validate her achievements but also highlight her rising influence in the field of molecular and cellular biology.

Research Focus:

Dr. Weili Miao’s research focuses on the molecular mechanisms by which small biomolecules regulate RNA-, DNA-, and protein-binding factors, with implications for gene expression, tissue development, and disease. At Stanford, she investigates how metabolites like glucose modulate RNA-binding proteins (e.g., DDX21, NSUN2), using integrative methods such as mass spectrometry, RNA-protein crosslinking, and structural analysis. Her work has uncovered how these interactions affect mRNA splicing, RNA stability, and translation—pivotal processes in differentiation and disease progression. Dr. Miao also advances novel tools for mapping protein interactions (e.g., PROBER, irCLIP-RNP), enabling more precise interrogation of functional biomolecular networks. Her long-term goal is to unravel the interplay between metabolism and gene regulation in health and disease. Through cutting-edge research, she bridges proteomics, RNA biology, and cell signaling, delivering insights that are both mechanistically profound and clinically relevant.

Publications Top Notes:

  1.  Regulation of RNA-binding proteins by small biomolecules, Nat. Rev. Mol. Cell Biol., 2025, in press

  2.  DDX50 cooperates with STAU1 to effect stabilization of pro-differentiation RNAs, Cell Rep., 2025

  3.  Disease-Linked Regulatory DNA Variants and Homeostatic Transcription Factors in Epidermis, Nat. Commun., 2025

  4.  Glucose binds and activates NSUN2 to promote translation and epidermal differentiation, Nucleic Acids Res., 2024

  5.  Glucose dissociates DDX21 dimers to regulate mRNA splicing and tissue differentiation, Cell, 2023

  6.  Targeted Proteomic Approaches for AMP-binding Capacities of Kinases, J. Proteome Res., 2022

  7.  Roles of N6-Methyladenosine in Heat Shock Response, J. Proteome Res., 2021

  8.  Kinome Reprogramming During Radiation Resistance in Breast Cancer Cells, J. Proteome Res., 2021

  9.  SARS-CoV-2 Spike Variants Bind Human ACE2 with Increased Affinity, Lancet Infect. Dis., 2021

  10.  Kinome Reprogramming During Melanoma Metastasis, Sci. Rep., 2020

Conclusion:

Dr. Weili Miao is a highly accomplished early-career scientist whose contributions to RNA biology and biomolecule interaction networks are both profound and innovative. Her ability to integrate quantitative proteomics, molecular biology, and structural techniques positions her uniquely within the biomedical research landscape. With an exceptional record of first-author publications, advanced technical skills, and independent funding secured, Dr. Miao not only meets but exceeds the standards for the Best Researcher Award. While expanding her translational footprint and leadership responsibilities could further solidify her trajectory, she is unequivocally a top-tier candidate deserving of recognition.

Chao Wang | Animal Nutrition | Best Researcher Award

Published on by Cell Biologist

Dr. Chao Wang | Animal Nutrition | Best Researcher Award

Dr. Chao Wang, Nanjing Agricultural University, China

Dr. Wang Chao is an Associate Professor at the College of Animal Science, Nanjing Agricultural University. He specializes in environmental biology, animal physiology, and soil carbon dynamics. Over the years, Dr. Wang has made impactful contributions to sustainable agriculture through his work on soil remediation, climate-resilient farming, and animal health. He has been the principal investigator for several prestigious projects, including those funded by the National Natural Science Foundation of China. With over 20 published articles in high-impact journals, his work bridges the disciplines of plant biology, environmental science, and veterinary studies. His recent research investigates how bioactive compounds like rutin improve animal resilience to stress. He is also exploring the genomic mechanisms underpinning plant adaptation and soil methane sink capacity. Dr. Wang’s holistic approach and interdisciplinary collaborations make him a valuable contributor to global sustainability efforts.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Diverse and High-Impact Research Portfolio:
    Dr. Wang Chao has published over 20 peer-reviewed articles across a range of impactful journals including Journal of Cleaner Production, Planta, Global Change Biology, and Nutrients. His research bridges several urgent scientific themes such as climate change, animal physiology, soil remediation, and genomics.

  2. Leadership in National Research Projects:
    He has served as the principal investigator for multiple national-level projects, including the National Natural Science Foundation of China, showcasing leadership in planning, funding acquisition, and execution of complex scientific studies.

  3. Interdisciplinary Research Scope:
    His work spans environmental sustainability, livestock health, plant genomics, and soil carbon sequestration, addressing both agricultural productivity and climate resilience.

  4. Focus on Practical Solutions:
    Dr. Wang’s research addresses real-world agricultural challenges such as saline-alkali land restoration, heat stress in poultry, and soil methane reduction, all of which align with global goals like carbon neutrality and food security.

  5. Recent Publications (2025):
    His recent papers demonstrate continued engagement with frontier topics and signal research activity at a high level in the current year.

Areas for Improvement:

  1. Citation Impact and Global Recognition:
    While his research is timely, most recent papers have 0 or 1 citation, likely due to their recency. Strategic dissemination through conferences, invited talks, and policy briefs could enhance reach and impact.

  2. International Collaborations and Patents:
    While national recognition is evident, more international joint publications or technology transfer (e.g., patents, industry partnerships) could elevate the global relevance of his work.

  3. Author Position Clarity:
    Author roles (first, last, corresponding) are not fully visible from the summary. Greater visibility as lead or senior author could strengthen his research leadership profile.

Education:

Dr. Wang Chao holds advanced degrees in Agricultural and Environmental Sciences. He earned his Ph.D. in Animal Science from Nanjing Agricultural University, focusing on biochemical and molecular responses to environmental stress in livestock. Prior to his doctorate, he completed his Master’s degree in Veterinary Medicine, where he explored nutrient metabolism and antioxidant mechanisms in poultry. His academic foundation was laid with a Bachelor’s degree in Animal Husbandry, equipping him with a broad understanding of animal genetics, physiology, and health. Throughout his academic career, Dr. Wang consistently demonstrated excellence, earning scholarships and research distinctions. He also undertook postdoctoral training in environmental sustainability and genomic biology, expanding his expertise into plant-soil interactions and climate-related impacts on agriculture. His diverse and rigorous academic background has enabled him to lead multidisciplinary research initiatives and mentor the next generation of scientists.

Experience:

Dr. Wang Chao currently serves as an Associate Professor at the College of Animal Science, Nanjing Agricultural University. Over his academic career, he has led and collaborated on numerous national-level projects, especially those funded by the National Natural Science Foundation of China. His teaching experience spans undergraduate and postgraduate levels, focusing on animal physiology, environmental toxicology, and sustainable agricultural systems. He has supervised numerous graduate theses and serves on several academic review boards. Dr. Wang also collaborates with researchers across environmental, biological, and agricultural sciences, contributing to multi-institutional studies on climate change and food security. His administrative duties include curriculum development, faculty coordination, and international research exchange programs. His experience reflects a balance of academic leadership, field research, and laboratory innovation, making him a well-rounded academic and a leading voice in eco-agriculture and animal health research.

Research Focus:

Dr. Wang Chao’s research centers around sustainable agriculture, animal environmental physiology, and soil-plant interactions. He investigates how abiotic stressors like heat and soil salinity impact animal metabolism and soil health. His work often focuses on natural compounds such as rutin and Lycium barbarum flavonoids, assessing their potential to mitigate oxidative stress and improve immune responses in livestock. In parallel, Dr. Wang explores carbon sequestration and soil multifunctionality in degraded and saline-alkali lands, helping to restore ecosystem services. His research also includes transposable elements in plant genomes, contributing to genetic resilience in crops. He combines fieldwork with molecular biology techniques, offering solutions for climate adaptation in agriculture. His studies on methane sink capacity of soils align with global carbon-neutral goals. Altogether, his research is distinguished by its interdisciplinary reach, real-world relevance, and focus on environmental sustainability.

Publications Top Notes:

  1.  Location-optimized remediation measures for soil multifunctionality and carbon sequestration of saline-alkali land in China – Journal of Cleaner Production

  2.  Genome-wide annotation and comparative analysis of miniature inverted-repeat transposable elements (MITEs) in six pear species – Planta

  3.  Rutin alleviates heat stress induced hepatic abnormal lipid metabolism of broilers via improving antioxidant capacity to maintain mitochondrial homeostasis – Journal of Thermal Biology

  4.  Generally Reduced Sink Capacity of Upland Soils for Atmospheric Methane Over the Past Three Decades (1993–2022) – Global Change Biology

  5.  Dietary Rutin Ameliorates Nanoparticle Zinc Oxide-Induced Toxicity in Mice by Potentiating Antioxidant Defense Mechanisms – Nutrients

  6.  Effects of Different Levels of Lycium barbarum Flavonoids on Growth Performance, Immunity, Intestinal Barrier and Antioxidant Capacity of Meat Ducks – Antioxidants

Conclusion:

Dr. Wang Chao is well-qualified and highly suitable for the Best Researcher Award based on the breadth, relevance, and scientific rigor of his work. His leadership in national projects, focus on sustainability and animal welfare, and consistent scholarly output in 2025 position him as a forward-thinking and impactful researcher. With growing international visibility and long-term citation impact, he has strong potential to emerge as a global leader in sustainable agricultural science.

Yanhua Liang | Signal Transduction Mechanisms | Best Researcher Award

Published on by Cell Biologist

Prof. Yanhua Liang | Signal Transduction Mechanisms | Best Researcher Award

Prof. Yanhua Liang, Shenzhen Hospital of Southern Medical University, China

Dr. Yan-Hua Liang,  is a distinguished dermatologist, academic, and researcher. He serves as Chairman and Chief Physician in the Department of Dermatology at Shenzhen Hospital, Southern Medical University. With over two decades of clinical and research experience, he is widely recognized for his contributions to dermatological science and translational medicine. Dr. Liang holds dual PhDs and has trained internationally, including a postdoctoral fellowship at The Jackson Laboratory in the U.S. His commitment to advancing psoriasis therapy, dermatological immunology, and healthcare system improvements is evident in his prolific publication record and mentorship roles. He actively collaborates with global experts and consistently publishes in high-impact journals. Through a career grounded in clinical excellence and research innovation, Dr. Liang continues to shape the field of dermatology in China and beyond.\

Publication Profile: 

Scopus

Strengths for the Award

  1. Proven Academic Excellence

    • Holds M.D., dual Ph.D.s, and completed a prestigious postdoctoral fellowship at The Jackson Laboratory, USA — reflecting strong scientific and international credentials.

  2. Clinical Leadership & Longstanding Experience

    • Over 20 years in dermatology, currently serving as Chairman and Chief Physician at a major university-affiliated hospital.

  3. Research Output & Innovation

    • 10+ high-quality peer-reviewed publications (2023–2025) in leading journals like Scientific Reports, Drug Safety, Frontiers in Medicine, and Dermatology.

    • Focus on real-world studies, biologic therapies, psoriasis, autoimmune skin diseases, and translational dermatology — addressing clinically relevant problems.

  4. Mentorship and Academic Contributions

    • Active Ph.D. supervisor, guiding the next generation of dermatological researchers.

    • Collaborates with both domestic and international institutions, boosting China’s contribution to global dermatology research.

  5. Multidisciplinary Impact & Public Health Relevance

    • Involved in infectious disease preparedness (Monkeypox) and healthcare system education for medical professionals.

Areas for Improvement

  1. International Visibility & Awards

    • While the academic record is strong, international keynote roles, global society leadership, or major global awards are not yet highlighted. These would further elevate his candidacy.

  2. Broader Interdisciplinary Integration

    • Could explore collaborative work in AI-driven dermatology, digital diagnostics, or bioinformatics, which are emerging fields in skin science.

Education (150 words)

Dr. Liang’s academic journey reflects a steadfast pursuit of medical excellence. He earned his Bachelor of Medicine from Gannan Medical University (1996–2001), followed by a Master of Science and Ph.D. in Dermatology from Anhui Medical University (2001–2007). To further enrich his scientific acumen, he completed a Postdoctoral Fellowship at The Jackson Laboratory, USA (2007–2010), a premier institution for biomedical research. His education combines strong clinical training with rigorous research methodology, particularly in genetics and dermatological sciences. Dr. Liang’s dual PhDs signify his interdisciplinary focus and commitment to integrating basic science into clinical innovation. His international training has enabled him to bridge Eastern and Western medical practices and adopt a global perspective in addressing skin diseases. With a strong foundation in immunodermatology, translational medicine, and evidence-based treatments, Dr. Liang’s academic background is a cornerstone of his success as a clinician-scientist and mentor.

Experience (150 words)

Dr. Yan-Hua Liang has over 20 years of experience in clinical dermatology and academic leadership. He currently holds the title of Chairman and Professor at the Department of Dermatology, Shenzhen Hospital, Southern Medical University (since 2016). Prior to this, he was a Professor at Nanfang Hospital, also part of Southern Medical University (2012–2015). His clinical expertise spans psoriasis, atopic dermatitis, and autoimmune skin diseases, with a focus on biologic therapies and translational dermatology. He has treated thousands of patients and led major clinical trials in China. As a Ph.D. supervisor, Dr. Liang has mentored numerous postgraduate students and emerging researchers. His leadership has helped modernize dermatological practices, elevate research standards, and foster international collaborations. Recognized for his medical innovations and deep patient care, Dr. Liang stands out as a thought leader in dermatology in the Greater Bay Area and nationally.

Research Focus (150 words)

Dr. Liang’s primary research interests lie in psoriasis treatment, immunodermatology, and translational skin research. He is a pioneer in real-world data analysis of biologic therapies for psoriasis, as demonstrated in several of his prospective, multicenter studies. His focus also includes the gut-skin axis, autoimmune dermatoses, and health policy studies aimed at improving access to dermatological care. In recent years, he has expanded his work into emerging infectious diseases like monkeypox, integrating public health into clinical dermatology. His work is often collaborative, involving multi-disciplinary teams and cross-border research. Dr. Liang is especially committed to improving healthcare delivery systems in dermatology, with a unique emphasis on evidence-based treatment, quality of life metrics, and healthcare worker training. His future focus aims to further explore microbiome-immune interactions in skin disease and introduce AI-driven diagnostic support systems. His research portfolio aligns with global dermatological priorities, positioning him as a leader in innovation and care.

Publications – One-line Format with Emojis

  1.  Cutaneous and systemic improvements in psoriasis after biologics in real-world study – Scientific Reports, 2025

  2.  Gut microbiota and psoriasis: A systematic review – Eur J Pharmacol, 2025

  3.  Hereditary Angioedema in China: Awareness and Advocacy from Greater Bay to Global – Clin Exp Allergy, 2025

  4.  Healthcare workers’ monkeypox knowledge and confidence survey – World J Clin Cases, 2025

  5.  Reducing recurrence of Condyloma Acuminatum via lesional auto-transplantation – J Cosmetics, Dermatol Sci Appl, 2024

  6.  Atopic Dermatitis: From Bench to Bedside – Front Med, 2024

  7.  Ixekizumab safety in Chinese plaque psoriasis patients – 12-week observational study – Drug Saf, 2024

  8. Effectiveness of Ixekizumab in special area involvement psoriasis patients – Dermatol Ther (Heidelb), 2024

  9. Quality of life and predictors of complete skin clearance in psoriasis – Dermatology, 2023

  10. Ixekizumab safety and efficacy in Chinese psoriasis patients – Prospective real-world study – Adv Ther, 2023

Conclusion

Dr. Yan-Hua Liang is a highly accomplished clinician-scientist whose integrated focus on clinical excellence, academic mentorship, and research productivity positions him as a leading candidate for the Best Researcher Award. His commitment to real-world research, particularly in psoriasis and biologic therapy, is both impactful and timely.

Given his sustained contributions, ongoing innovative work, and national academic leadership, Dr. Liang exemplifies the qualities of a modern, translational researcher who is significantly advancing dermatology in China and beyond.

Hannah Wen | Breast Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Hannah Wen | Breast Cancer | Best Researcher Award

Dr. Hannah Wen, MEMORIAL SLOAN KETTERING CANCER CENTER, United States

Dr. Hannah Y. Wen, M.D., Ph.D., is a distinguished breast cancer pathologist and cancer researcher at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. With dual training in medicine and cancer biology, Dr. Wen’s career reflects a deep commitment to advancing the field of translational oncology. Her research focuses on triple-negative breast cancer (TNBC), rare breast tumor subtypes, and predictive/prognostic biomarkers. Dr. Wen is a prolific academic contributor with publications in high-impact journals such as Nature Communications and Cancer Research. She integrates molecular biology with diagnostic pathology to improve cancer stratification and therapy decisions. In addition to her investigative work, she contributes as a principal investigator on multiple IRB-approved studies at MSKCC. Recognized with early academic accolades and continuously advancing the frontiers of cancer pathology, Dr. Wen exemplifies the blend of scientific rigor and clinical relevance. She is a strong candidate for any prestigious research award in pathology and oncology.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Academic Training
    Dr. Wen holds an M.D. from Peking University Health Science Center, one of China’s top medical schools, and a Ph.D. in Cancer Biology from MD Anderson Cancer Center, a global leader in cancer research.

  2. Robust Postdoctoral and Clinical Research Experience
    Her postdoctoral work at Genentech Inc. and ongoing clinical-scientific role at Memorial Sloan Kettering Cancer Center (MSKCC) place her at the intersection of innovative molecular research and high-impact clinical diagnostics.

  3. High-Impact Publications
    She has authored landmark papers in journals like Cancer Research, Nature Cell Biology, PNAS, Modern Pathology, and Nature Communications, covering diverse areas such as:

    • Triple-negative breast cancer

    • Genetic markers (e.g., BRCA1, p202)

    • Molecular subtyping of rare breast tumors

    • Pathologic stratification of early-stage breast cancer

  4. Active Investigator and IRB Leadership
    Dr. Wen is Principal Investigator for multiple MSK IRB protocols involving rare breast cancer subtypes and molecular markers. This shows strong leadership in translational research.

  5. Recognition and Consistency
    From receiving Top 10 Student Awards in Beijing to leading diagnostic-pathologic breakthroughs in 2025, her excellence spans over three decades.

Areas for Improvement:

  1. Visibility of Awards in the U.S. Academic System
    While her early academic awards are impressive, more documented recent honors, society memberships, or fellowships could further enhance her candidacy.

  2. Mentorship and Teaching Roles
    While likely involved, specific mention of mentorship, educational leadership, or curriculum development would strengthen her profile in academic impact.

  3. Interdisciplinary Collaborations
    Explicit examples of cross-disciplinary collaborations (e.g., computational oncology, AI in pathology) would underscore her innovation potential in modern biomedical research.

Education:

Dr. Hannah Y. Wen obtained her M.D. from Peking University Health Science Center, Beijing, China (1988–1993), where she was consistently recognized as an outstanding student. She pursued her Ph.D. in Cancer Biology at the University of Texas Health Science Center/MD Anderson Cancer Center in Houston, TX (1997–2001), focusing on molecular oncology. During her Ph.D., she contributed significantly to understanding interferon-inducible proteins in cancer suppression. Her educational journey reflects deep interdisciplinary training, combining clinical medicine with cutting-edge research. This robust academic background has laid the foundation for her success in translational cancer research and diagnostic pathology. Dr. Wen’s training continues with postdoctoral work at Genentech Inc. in Experimental Pathology, which further honed her molecular diagnostic skills. Her global academic trajectory—from China to elite U.S. institutions—has shaped her into a well-rounded researcher capable of addressing complex challenges in breast cancer diagnosis and treatment.

Experience:

Dr. Wen brings over two decades of research and clinical experience in cancer biology and diagnostic pathology. After completing her Ph.D. at MD Anderson Cancer Center, she conducted postdoctoral research in Experimental Pathology at Genentech, Inc., South San Francisco (2002–2003). Since then, she has held a faculty position at the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center. At MSKCC, Dr. Wen has served as Principal Investigator on multiple IRB-approved protocols investigating rare breast cancer subtypes and genetic alterations. Her daily work bridges histopathology and genomics to advance precision medicine in breast cancer. Beyond research, she mentors fellows and contributes to academic committees, reinforcing her role as a leader in her field. Her hands-on experience with triple-negative breast cancer, breast tumor markers, and breast pathology variants gives her a rare clinical-research dual expertise, making her a vital figure in contemporary breast cancer diagnostics.

Awards and Honors:

Dr. Hannah Y. Wen has received numerous recognitions throughout her academic journey. Early in her career, she was honored with the Outstanding Student Award by Peking University Health Science Center (1988–1992), a distinction granted to top-tier medical students. She was also named among Beijing’s Top 10 Outstanding Students in 1992, recognizing her academic and leadership excellence. While formal awards during her U.S. career are not extensively documented in the data provided, Dr. Wen’s growing impact in high-impact journals and role as a Principal Investigator at MSKCC are implicit accolades in the competitive world of academic medicine. Her contributions to translational breast cancer research, including studies on BRCA1 inactivation and tumor progression markers, underscore her continuous excellence. Given her record of impactful research and professional standing at one of the world’s leading cancer centers, she remains a strong contender for recognition such as the Best Researcher Award.

Research Focus:

Dr. Wen’s research centers on triple-negative breast cancer (TNBC), a challenging and aggressive subtype of breast cancer with limited therapeutic targets. She also investigates rare and under-recognized breast tumor subtypes such as microglandular adenosis, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. Her work involves the identification of predictive and prognostic markers, employing techniques such as targeted gene sequencing, BRCA1 methylation analysis, and molecular stratification models. As Principal Investigator, she leads studies under MSK IRB Protocols #16-411 and #16-596, exploring the genomic and epigenetic landscape of TNBC. Her research stands out for its clinical translation, directly impacting patient diagnosis and treatment planning. Recent contributions to Nature Communications and Modern Pathology show her innovative use of multimodal histopathological models and molecular profiling. Dr. Wen’s research reflects a powerful blend of diagnostic pathology, molecular genetics, and precision oncology—positioning her as a leader in breast cancer research.

Publications Top Notes:

  1.  The Role of Platelet Activating Factor in Reproduction – Progress of Anatomical Sciences (1996)

  2.  Transforming Growth Factor-α and Its Receptor in Reproduction – Medical Sciences (1997)

  3.  TGF-α Expression in Mouse Embryos and Uterus – J. Beijing Medical Univ. (1997)

  4.  p202 Slows Prostate Cancer Cell Growth – Oncogene (1999)

  5.  p202 Enhances TNF-α-Induced Apoptosis in Breast Cancer – Cancer Research (2000)

  6.  β-catenin as a Prognostic Marker in Breast Cancer – PNAS USA (2000)

  7.  HER-2/neu Drives Androgen-Independent Prostate Cancer – Cancer Research (2000)

  8.  EGFR’s Nuclear Role as a Transcription Factor – Nature Cell Biology (2001)

  9.  p202 Mediates Anti-Tumor Activity in Pancreatic Cancer – Cancer Research (2001)

  10.  Systemic Tumor Suppression via Bik Gene – Cancer Research (2002)

Conclusion:

Dr. Hannah Y. Wen is a highly qualified and deserving nominee for the Best Researcher Award. Her outstanding academic background, consistent and impactful research output, and leadership in breast cancer pathology make her a top-tier researcher in the field of translational oncology. She excels in integrating molecular biology with diagnostic pathology to improve cancer detection, stratification, and treatment.

With minor enhancements in visibility and cross-disciplinary leadership, Dr. Wen is not only suitable but a model candidate for this award. Her work is advancing breast cancer care at both the bench and bedside—fulfilling the core mission of research excellence.

Xingle Zhao | Gene Therapy of Hearing Loss | Best Researcher Award

Published on by Cell Biologist

Dr. Xingle Zhao | Gene Therapy of Hearing Loss | Best Researcher Award

Dr. Xingle Zhao, The First Affiliated Hospital of Zhengzhou University, China

Dr. Xingle Zhao is a dedicated biomedical researcher with a Ph.D. in Surgery from Shanghai Jiaotong University, focusing on inner ear gene therapy. With a robust academic foundation from Wuhan University and a research journey spanning over a decade, he has contributed significantly to auditory neuroscience. His groundbreaking work in cochlear gene therapy has led to several high-impact publications, including in Nature Communications and Human Gene Therapy. Dr. Zhao’s research centers on advancing therapeutic interventions for hearing loss using adeno-associated virus (AAV)-mediated gene delivery and CRISPR-based editing in murine models. Passionate about translating research into clinical potential, he is recognized for his innovative strategies to restore auditory function. His commitment to excellence and innovation places him as a strong candidate for the Best Researcher Award.

Publication Profile: 

Orcid

 Strengths for the Award:

  1.  Strong Publication Record in High-Impact Journals
    Dr. Zhao has published in top-tier journals such as Nature Communications, Human Gene Therapy, and Molecular Therapy – Methods & Clinical Development. This reflects both the scientific significance and rigor of his work.

  2.  Niche Yet Impactful Research Focus
    His expertise in gene therapy for inner ear disorders is highly specialized and innovative. His work directly contributes to addressing sensorineural hearing loss, a critical unmet medical need.

  3.  Technical Mastery and Innovation
    Dr. Zhao demonstrates advanced skills in using AAV-mediated gene delivery, CRISPR/Cas9, transcriptomic analysis, and base editing—technologies at the forefront of molecular medicine.

  4.  Collaborative Researcher
    He has successfully collaborated with multiple research teams and institutions, showing strong team science orientation, often essential in translational biomedical research.

  5.  Translational Impact
    His research moves beyond basic science to show real therapeutic potential, such as day-one hearing restoration in adult deaf mice using AAV8-mediated Vglut3 rescue—a milestone in preclinical gene therapy.

Areas for Improvement:

  1.  Limited International Exposure
    While his work is high quality, more international collaborations or fellowships could increase his global visibility and broaden the impact of his research.

  2.  Public and Clinical Translation Pathways
    A focus on translating findings into clinical trials, and greater involvement in science communication or patent filings, would enhance the practical application of his discoveries.

  3.  Mentorship and Outreach
    Expanding roles in mentorship, teaching, or scientific leadership could amplify his influence and contribute to academic community-building.

Education:

Dr. Xingle Zhao completed his Ph.D. in Surgery at Shanghai Jiaotong University (2017–2023), where he specialized in gene therapy for inner ear disorders. His doctoral research led to a series of influential publications, pushing forward the understanding and treatment of sensorineural hearing loss through genetic strategies. He focused on AAV vector development, gene editing, and functional restoration in animal models. Prior to his doctoral studies, he earned his Bachelor’s degree in Surgery at Wuhan University (2012–2017). There, he built a solid clinical and anatomical foundation, gaining early exposure to surgical principles and developing core competencies in patient care. His academic training combined cutting-edge biomedical research with real-world medical applications, enabling him to bridge laboratory findings with translational potential. Dr. Zhao’s educational background is rooted in two of China’s leading institutions, reinforcing both his technical rigor and academic integrity.

Experience:

Dr. Xingle Zhao brings a decade of experience in gene therapy and auditory neuroscience. During his Ph.D. at Shanghai Jiaotong University, he led and co-authored multiple studies on cochlear gene editing and therapeutic restoration in mouse models, particularly targeting genes such as Vglut3 and Otoferlin. He has hands-on expertise in AAV vector design, CRISPR-Cas9 technologies, in vivo cochlear injection, and molecular analysis. His role extended from lab-based research to collaborative team science, working with clinicians, molecular biologists, and geneticists across disciplines. Notably, he contributed to a high-impact Nature Communications paper and published in Human Gene Therapy and Hearing Research. Dr. Zhao also demonstrated mentoring capacity with junior researchers and was actively involved in presenting his work at scientific forums. His experience spans preclinical experimentation, data interpretation, and translational strategies, making him highly proficient in targeted gene therapy development for hearing restoration.

Research Focus:

Dr. Xingle Zhao’s research is centered on genetic therapies for hearing loss, with an emphasis on restoring auditory function via gene delivery systems. His work focuses on the development and application of adeno-associated virus (AAV) vectors, CRISPR/Cas9 editing tools, and promoter optimization for inner ear gene targeting. A particular emphasis is placed on rescuing hearing loss in adult and neonatal mouse models, notably targeting genes such as Vglut3 and Otof. His research highlights the potential of rapid gene therapy as a practical intervention in auditory impairment, bridging basic science with potential clinical treatments. Dr. Zhao also investigates the transcriptomic diversity of cochlear genes, uncovering isoform-specific roles in auditory physiology. His vision is to enable safe, efficient, and long-lasting gene therapy protocols that can be translated into future human therapies for sensorineural deafness. This niche yet impactful domain places him at the forefront of auditory gene therapy innovation.

Publication Top Notes: 

  1.  Cochlear transcript diversity and its role in auditory functions implied by an otoferlin short isoform – Nature Communications (2023)

  2.  Gene Therapy Restores Auditory Functions in an Adult Vglut3 Knockout Mouse Model – Human Gene Therapy (2022)

  3.  Characterization of promoters for adeno-associated virus mediated efficient Cas9 activation in adult Cas9 knock-in murine cochleae – Hearing Research (2020)

  4.  Adeno-associated virus vector enables safe and efficient Cas9 activation in neonatal and adult Cas9 knock-in murine cochleae – Gene Therapy (2020)

  5.  Gene editing-based hearing impairment research and therapeutics – Neuroscience Letters (2019)

  6.  A review of application of base editing for the treatment of inner ear disorders – Journal of Bio-X Research (2019)

  7.  Rapid Cochlear Gene Therapy in Adult Deaf Mice: Vglut3 Rescue via AAV8 Achieves Day-1 Hearing Restoration – Molecular Therapy Methods & Clinical Development (2025)

Conclusion:

Dr. Xingle Zhao is a highly suitable candidate for the Best Researcher Award. His impactful work in gene therapy, focused on restoring hearing through precise molecular interventions, represents a significant scientific advancement with strong translational promise. He brings together academic rigor, innovation, and collaboration—hallmarks of a leading biomedical researcher. While expanding global collaboration and clinical engagement could further strengthen his profile, his current contributions already position him as a rising star in auditory genetics and molecular therapeutics.

Chetan Shinde | Genetics and Plant Breeding | Young Scientist Award

Published on by Cell Biologist

Mr. Chetan Shinde | Genetics and Plant Breeding | Young Scientist Award

Mr. Chetan Shinde, Mahatma Phule Krishi Vidyapeeth, Rahuri, India

Mr. Shinde Chetan Subhash is a dedicated and passionate agricultural researcher from India with a strong academic foundation and significant contributions to plant genetics and breeding. Known for his positive thinking, excellent presentation skills, and remarkable stage courage, he has demonstrated leadership from his undergraduate days, including his involvement in NSS and technical councils. With a keen interest in crop improvement and biotechnology, Mr. Shinde has co-authored two books and published over 15 peer-reviewed research articles in reputed journals. His work focuses on genetic diversity, molecular characterization, and breeding strategies for crops like soybean, rice, and millet. He shows great promise as a young scientist committed to advancing agricultural innovation. His academic excellence, practical exposure, and publication record make him a valuable contributor to the scientific community.

Publication Profile: 

Google scholar

Strengths for the Award:

  1. Outstanding Academic Performance

    • Secured 89.60% in M.Sc. (Agri.) and 88.70% in B.Sc. (Agri.), both with First Class Distinction from prestigious institutes under Mahatma Phule Krishi Vidyapeeth, Rahuri.

  2. Robust Research Publication Profile

    • Co-authored 15+ research articles in reputed, peer-reviewed national and international journals.

    • Authored 2 academic books on Plant Breeding and Genetics and Biotic Stress Resistance, published by respected publishers.

  3. Diverse and Applied Research Focus

    • Research spans crop improvement, genetic diversity, molecular marker-assisted selection, stress resistance, and microbial consortia, with applications to rice, soybean, pearl millet, finger millet, and moringa.

  4. Technical and Leadership Engagement

    • Served as an NSS volunteer and participated in rural development activities.

    • Member of the All India Council for Technical Skill Development, reflecting commitment to national agricultural capacity building.

  5. Professional Strengths

    • Demonstrates positive thinking, presentation skills, and stage courage—key traits for academic dissemination and leadership in research.

Areas for Improvement:

  1. Global Exposure & Collaborations

    • Can benefit from engaging in international conferences, research networks, or joint publications to enhance global scientific presence.

  2. Advanced Data Analytics

    • Opportunity to deepen skills in bioinformatics, genomics data analysis, and AI applications in plant breeding for future-ready research.

  3. Research Commercialization or Field Application

    • Encouraged to explore technology transfer, patent filings, or on-ground trials that connect his research to real-world farming outcomes.

Education:

Mr. Shinde Chetan Subhash holds an M.Sc. (Agri.) in Genetics and Plant Breeding (2022) from the College of Agriculture, Pune, under Mahatma Phule Krishi Vidyapeeth, Rahuri, securing 89.60% with first class distinction. He earned his B.Sc. (Agri.) in 2020 from Shramashakti College of Agriculture, Maldad, also affiliated with MPKV Rahuri, graduating with 88.70% and first class with distinction. His strong academic record is complemented by active co-curricular participation, including serving as an NSS volunteer and engaging in technical skill development activities. Throughout his academic career, he has consistently excelled in both theoretical and practical aspects of agricultural science. His education has laid a solid foundation for his current research pursuits in crop genetics, plant breeding, and biotechnology, with a specific interest in improving genetic traits and addressing challenges related to biotic stress in crops.

Experience:

Mr. Shinde has an impressive background in both academic and applied agricultural research. During his M.Sc. and B.Sc. studies, he gained hands-on experience in field trials, molecular marker analysis, and statistical evaluation of crop performance. His involvement in multiple research projects has allowed him to collaborate with reputed scientists across India. He has actively participated in NSS rural development programs and is a member of the All India Council for Technical Skill Development. Mr. Shinde’s practical experience is evident from his diverse publication portfolio, including topics on genetic variability, microbial consortia, land use implications, and drought tolerance in crops. His contributions span both classical breeding techniques and modern molecular tools. He has also co-authored two books on plant breeding and biotic stress resistance, showcasing his versatility and scholarly engagement. He is well-prepared for independent research and future leadership in plant science innovation.

Research Focus:

Mr. Shinde’s research is centered on Genetics and Plant Breeding, with an emphasis on improving crop performance under stress conditions. His work spans molecular characterization, development of microbial consortia for nutrient management, and genetic diversity analysis in major crops like rice, soybean, pearl millet, drumstick, and finger millet. He utilizes classical breeding methods and integrates modern biotechnological approaches, including marker-assisted selection. His interest in drought tolerance, biotic stress resistance, and sustainable crop productivity addresses critical agricultural challenges. Notably, he has contributed to molecular research on Kunitz Trypsin Inhibitor and lipoxygenase genes in soybean, ecological land use dynamics, and nutrient optimization in legumes. Through interdisciplinary collaboration, Mr. Shinde has positioned himself at the forefront of agricultural innovation. His work is aligned with the goals of food security, climate resilience, and genetic conservation. He aspires to contribute further to national and global agricultural research as a young scientist.

Publications Top Notes: 

  1. 📘 Plant Breeding and Genetics: Present Concepts and Approaches – Volume 2 (Book)

  2. 📗 Biotic Stress Resistance in Horticultural Crops (Book)

  3. 📝 Evaluation of Wheat [Triticum aestivum (L.)] Genotypes in Response to Late Sown Conditions

  4. 🌱 Development of Microbial Consortia for Nutrient Supplementation to Chickpea

  5. 🌍 Ecological Implications of Land Use Dynamics in Western Maharashtra

  6. 🌾 Estimation of Genetic Variability in Pearl Millet (Pennisetum glaucum L.)

  7. 🌿 Association of Characters and Path Coefficient Analysis in Fodder Drumstick

  8. 🌾 Evaluation of Genetic Divergence in Rice (Oryza sativa L.) Genotypes

  9. 🧬 Identification of Soybean Segregants for Kunitz and Lipoxygenase Genes via Molecular Markers

  10. 🌱 Genetic Variability Studies in Fodder Drumstick (Moringa oleifera L.)

Conclusion:

Mr. Shinde Chetan Subhash is highly suitable for the Research for Young Scientist Award. His academic excellence, multi-dimensional research contributions, and commitment to agricultural innovation strongly align with the award’s purpose—to encourage and recognize emerging researchers. His work bridges traditional breeding and modern biotechnology with a clear focus on sustainable and productive agriculture.

With continued mentorship and strategic research direction, he holds the potential to become a leading young scientist in India’s agri-biotech and crop improvement ecosystem.

Subhani Okarvi | Molecular Imaging | Innovative Research Award

Published on by Cell Biologist

Prof. Dr. Subhani Okarvi | Molecular Imaging | Innovative Research Award

Prof. Dr. Subhani Okarvi, KFSHRC, Saudi Arabia

Dr. Subhani Mohammad Okarvi is a distinguished Senior Medical Scientist and Section Head of the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre. With over three decades of expertise in radiopharmaceutical sciences, Dr. Okarvi has significantly contributed to the design, synthesis, and evaluation of novel radiolabeled peptides for cancer diagnostics and therapy. His pioneering research focuses on developing peptide-based agents labeled with radionuclides like ⁶⁸Ga, ¹⁷⁷Lu, and ⁸⁹Zr, which aid in targeting tumors such as breast and ovarian cancers. Dr. Okarvi is internationally recognized through numerous publications and collaborative efforts that enhance nuclear medicine applications in oncology. His commitment to translational research and quality control in clinical radiopharmaceutical production makes him an invaluable asset to the scientific community.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Pioneering Research in Radiopharmaceuticals
    Dr. Okarvi has made significant and sustained contributions to the field of radiopharmaceutical sciences, particularly in the development of peptide-based radiotracers for cancer imaging and therapy.

  2. Innovation in Peptide Engineering
    He has developed and evaluated numerous novel radiolabeled peptides, including agents targeting estrogen receptors, Mucin1, Folate receptors, and integrins, demonstrating originality in design and clinical relevance.

  3. Multidisciplinary Integration
    His work intersects medicinal chemistry, molecular biology, and nuclear medicine, showing strong translational value from bench to bedside.

  4. High-Impact Publications
    With over 15 peer-reviewed journal articles (many in leading journals such as EJNMMI Radiopharmacy and Chemistry, Cancer Biotherapy and Radiopharmaceuticals, and Molecules), his research is widely recognized and cited.

  5. Leadership in Clinical Translation
    At King Faisal Specialist Hospital and Research Centre, he leads the production and quality control of clinically used radiopharmaceuticals (⁹⁹ᵐTc, ⁶⁸Ga, ¹⁷⁷Lu, ⁸⁹Zr), reflecting real-world healthcare impact.

  6. International Recognition
    His fellowships from Katholieke Universiteit Leuven and the Alberta Cancer Board, and his collaborative work across borders, reflect international appreciation of his contributions.

Areas for Improvement:

  1. Patent & Commercialization Activity
    While Dr. Okarvi’s research has strong translational potential, more structured efforts in patenting and commercializing his peptide constructs would broaden their impact.

  2. Broader Interdisciplinary Outreach
    Collaborations with AI, data science, and theranostic platforms could elevate the reach of his innovations in the next phase of precision medicine.

  3. Global Thought Leadership
    Increased participation as a keynote speaker, panelist, or editorial board member in international forums would boost his visibility and influence within the scientific community.

Education:

Dr. Subhani M. Okarvi’s academic journey began with a Bachelor’s in General Sciences (1984) and Pharmacy (1986) from the University of Karachi, Pakistan. He further pursued advanced studies in Europe, completing his Master of Science (1989) and Ph.D. (1992) in Radiopharmaceutical Sciences from Katholieke Universiteit Leuven, Belgium—one of Europe’s premier research institutions. His graduate and doctoral research provided a strong foundation in the synthesis, radiolabeling, and biological evaluation of peptide-based radiopharmaceuticals. This multidisciplinary training combined pharmaceutical chemistry, radiochemistry, and nuclear medicine, equipping Dr. Okarvi with the tools needed to develop innovative diagnostic and therapeutic agents for oncology. His robust educational background reflects both academic excellence and deep specialization in a critical niche of medical science.

Experience:

Since 1999, Dr. Subhani M. Okarvi has served as Senior Medical Scientist and Section Head at King Faisal Specialist Hospital and Research Centre’s Cyclotron and Radiopharmaceuticals Department. He leads efforts in the synthesis, radiochemical processing, and preclinical evaluation of novel radiopharmaceuticals targeting breast, ovarian, and other cancers. His role includes supervising the production and quality control of radiotracers such as ⁹⁹ᵐTc, ⁶⁸Ga, ¹⁷⁷Lu, and ⁸⁹Zr for clinical use. Dr. Okarvi’s leadership extends to mentoring junior scientists and fostering research collaborations. His expertise spans in vitro and in vivo assays, solid-phase peptide synthesis, and regulatory aspects of radiopharmaceutical development. His work bridges the gap between laboratory innovation and bedside application, making him instrumental in advancing nuclear medicine practices in Saudi Arabia and globally.

Awards and Honors:

Dr. Subhani M. Okarvi has earned several prestigious awards and fellowships in recognition of his scientific excellence. During his doctoral studies at Katholieke Universiteit Leuven, he was awarded the Onderzoeksfonds Postgraduate Fellowship (1990–1992), a testament to his promising research trajectory. He later received the Alberta Cancer Board Fellowship (1995–1998), supporting his oncology-focused research in Canada. In 1997, he was honored with a Travel Grant from the Alberta Heritage Foundation for Medical Research, enabling international scientific exchange. These accolades highlight both his academic merit and the translational relevance of his work. His contributions continue to impact radiopharmaceutical science through groundbreaking cancer imaging and therapy innovations. These awards underscore his dedication, influence, and continued pursuit of scientific advancement in nuclear medicine.

Research Focus:

Dr. Subhani Okarvi’s research focuses on the development of novel peptide-based radiopharmaceuticals for molecular imaging and targeted radionuclide therapy. He specializes in synthesizing and radiolabeling biomolecules with isotopes such as ⁶⁸Ga, ¹⁷⁷Lu, ¹⁸F, and ⁸⁹Zr for the detection and treatment of breast, ovarian, and hypoxic tumors. His studies aim to improve the precision of PET and SPECT imaging by targeting biomarkers like estrogen receptors, Mucin1, folate receptors, and integrins. His research combines chemistry, pharmacology, and imaging sciences, leading to multiple high-impact publications and promising preclinical candidates. Dr. Okarvi is particularly invested in hybrid peptide constructs and solid-phase synthesis methods that enhance binding affinity, tumor selectivity, and in vivo stability. His work has a strong translational focus—moving lab discoveries to clinical applications. The ultimate goal is to improve early cancer diagnosis and personalize therapy using cutting-edge radiopharmaceuticals.

Publications Top Notes:

  1. 🧪 Solid-phase synthesis and in vitro and in vivo evaluation of novel Estradiol derivatives for targeting estrogen-receptor positive breast cancer (2025 – Manuscript Ready)

  2. 🧬 Preparation and preclinical evaluation of ¹⁸F-labeled folate-RGD conjugate for PET imaging of triple-negative breast carcinoma (2024 – Submitted)

  3. 🧠 Synthesis and preclinical evaluation of ⁸⁹Zr-labeled Angiotensin peptide as a breast cancer imaging agent (2024 – Abstract, Eur. J. Nucl. Med.)

  4. 🔬 Preparation, radiolabeling with ⁶⁸Ga/¹⁷⁷Lu and preclinical evaluation of novel Angiotensin peptide analog for breast cancer targeting (2023 – Pharmaceuticals)

  5. ❤️‍🔥 Development of new ⁶⁴Cu-labeled Rhodamine: A potential PET myocardial perfusion imaging agent (2022 – EJNMMI Radiopharmacy)

  6. 🎯 Synthesis, radiolabeling and preclinical evaluation of ⁶⁸Ga/¹⁷⁷Lu-labeled Leuprolide peptide analog for breast cancer detection (2022 – Cancer Biother. & Radiopharm.)

  7. 🌫️ Synthesis and in vitro and in vivo evaluation of a new ⁶⁴Cu-semicarbazone complex for hypoxic tumors (2022 – Abstract)

  8. 👩‍⚕️ Synthesis, radiolabeling and biological evaluation of ⁶⁸Ga-Mucin1 and folate hybrid peptide conjugates for ovarian cancer diagnosis (2021 – Journal of Chemistry)

  9. 🧬 Fast ¹⁸F labeling and preclinical evaluation of Mucin1-Folate hybrid peptide conjugate for targeting breast carcinoma (2021 – EJNMMI Radiopharmacy)

  10. 🧪 Preclinical evaluation of ⁶⁸Ga-NODAGA-MUC1 and its folate hybrid conjugates for breast/ovarian cancer imaging (2021 – Abstract)

Conclusion:

Dr. Subhani Mohammad Okarvi is highly suitable and strongly recommended for the Innovative Research Award.

His research in novel radiopharmaceuticals has demonstrated:

  • Significant scientific originality

  • Clear translational impact in nuclear medicine

  • Consistent academic excellence

  • Strong leadership in clinical application

With over three decades of focused, cutting-edge work in cancer-targeting agents, he exemplifies the kind of innovator the award aims to recognize. Continued support and recognition will further empower his efforts to advance personalized cancer diagnostics and therapy.